Radioactive diagnostic agent indicated for positron emission tomography (pet) of prostate specific membrane antigen (psma) positive lesions in men with prostate cancer.
Ended Awarded Last action
- Contract number
- 36C26123A0014
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Task orders
- 4 $4,607,909 obligated
Award facts
- Opportunity
-
- 36C26123Q0135 Solicitation number
- Combined order value
- $4,607,909 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 84% used
- $5,500,000.00
- Maximum order
- $1,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Veterans Integrated Service Network 21 established a Blanket Purchase Agreement with Progenics Pharmaceuticals Inc. on January 15, 2023, against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), for radioactive diagnostic agents indicated for positron emission tomography imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer, with a $5.5 million ceiling and a total small business set-aside designation.
The BPA covers performance at the awardee's facility in North Billerica, Massachusetts, under a firm fixed-price structure through December 31, 2025. BPA calls under this vehicle have included a $506,420.80 call issued February 1, 2023 for radioactive diagnostic agents; an $864,884.08 call issued October 1, 2023 for PYLARIFY (piflufolastat F-18) covering October 1, 2023 through September 30, 2024; a $1,502,418.80 call issued October 1, 2024 for option year one with ultimate completion September 30, 2025; and a $1,734,185.60 call issued October 1, 2025 for 480 doses of PYLARIFY covering January 1 through December 31, 2025, with ultimate completion September 26, 2026.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36C26123A0014?
36C26123A0014 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on January 15, 2023.
How much is contract 36C26123A0014 worth?
Orders under 36C26123A0014 have obligated $4,607,909. 36C26123A0014's own ceiling is $5,500,000. A single order can be worth up to $1,500,000.
How many orders have been placed under contract 36C26123A0014?
4 orders have been placed under 36C26123A0014, the latest on October 1, 2025.
Who can order from contract 36C26123A0014?
36C26123A0014 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36C26123A0014 under another contract?
Yes. 36C26123A0014 is a blanket purchase agreement under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26123A0014 competed?
The extent of competition for 36C26123A0014 was full and open competition. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV